Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $26.75.

A number of research firms have issued reports on SEPN. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price objective on shares of Septerna in a report on Thursday, August 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Septerna in a report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Septerna from a “sell” rating to a “hold” rating in a report on Sunday, September 21st.

Septerna Trading Down 1.7%

NASDAQ SEPN opened at $21.94 on Thursday. The company has a fifty day simple moving average of $17.65 and a 200 day simple moving average of $12.68. Septerna has a 12-month low of $4.17 and a 12-month high of $28.99. The company has a market cap of $978.09 million and a P/E ratio of -2.17.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. Sell-side analysts predict that Septerna will post -7.11 EPS for the current year.

Institutional Investors Weigh In On Septerna

A number of hedge funds have recently made changes to their positions in SEPN. KLP Kapitalforvaltning AS bought a new stake in shares of Septerna during the 1st quarter worth $49,000. Chicago Partners Investment Group LLC bought a new stake in shares of Septerna during the 1st quarter worth $63,000. Deutsche Bank AG raised its stake in shares of Septerna by 53.3% during the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock worth $92,000 after purchasing an additional 5,549 shares during the period. Stoneridge Investment Partners LLC bought a new stake in shares of Septerna during the 1st quarter worth $107,000. Finally, PharVision Advisers LLC bought a new stake in shares of Septerna during the 2nd quarter worth $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.